Please assess the completion status of the following clinical trial:

Trial Title: Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with ADPKD with polycystic liver (\> 20 liver cysts)~* Renal function MDRD \>40 ml/hr~* Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements~Exclusion Criteria:~* Kidney transplantation~* Renal failure requiring hemodialysis~* Use of oral contraceptives or estrogen suppletion~* Women who are pregnant or breastfeeding~* History of cardiac/pulmonary disease; symptomatic gallstones, pancreatitis, etc~* Intervention (aspiration or surgical intervention) within three months from baseline~* Treatment with somatostatin analogues within three months from baseline~* Mental illness that interferes with the patient ability to comply with the protocol~* Drug or alcohol abuse within one year from baseline~* Abnormal liver function tests, as determined by blood test (except isolated elevated GGT and AP, which occurs frequently in PLD)~* Clinical diagnosis of pancreatitis~* Diagnosis of diabetes mellitus, as determined by blood test and medical history~* Use of drugs that can interact with lanreotide, such as cyclosporin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lanreotide (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).